You are here: Industry Insights > ProBioGen

News List

ProBioGen's GlymaxX® Technology Reaches Phase III Clinical Development B3Cnewswire
December 20, 2021
ProBioGen, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for its GlymaxX antibody-dependent cellular cytotoxicity (ADCC) enhancement technology.
ProBioGen's GlymaxX® Technology Made It Again into Clinical Phase I B3Cnewswire
November 18, 2021
ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another product candidate applying its antibody-dependent cellular cytotoxicity...
Nobelpharma Signs License Agreement to Use ProBioGen’s Vaccine Production Platform contractpharma
August 13, 2021
The cell-based system for vaccine production offers a cost-effective, efficient and flexible alternative to traditional vaccine production.
Nobelpharma Signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX® b3cnewswire
August 13, 2021
ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIXvaccine production platform to develop their lead vaccine.
ValenzaBio, ProBioGen Enter Cell Line Pact contractpharma
July 29, 2021
ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen's GlymaxX technology.
ValenzaBio Partners with ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX® b3cnewswire
July 28, 2021
ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.
Heat Biologics Enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line b3cnewswire
July 14, 2021
ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System DirectedLuck™ as well as for their proprietary suspension HEK293 cell line.
ProBioGen and LAVA Therapeutics sign cell line development agreement cphi-online
June 24, 2021
The agreement marks the second cell line development collaboration between the two companies
ProBioGen, LAVA to Develop Cell Lines for Bispecific Candidate contractpharma
June 23, 2021
ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform.
ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific b3cnewswire
June 23, 2021
ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.

Previous page 1 2 3 4 5 6 Next page